Neuralink pre-IPO via Binaryx — four layers between the investor and the share
Data as of 3 Sep 2026.
Bottom line: three independent reasons, each enough on its own. Structure: the buyer gets a token from a Wyoming company, behind which sits a series of a Delaware fund registered on 25 June 2026; shares are bought after the money is raised, and from whom is stated nowhere. Price: entry at $44bn against the only real round of $9.65bn (June 2025) and independent marks of $29–42bn; the markup eats about 36% of the upside in the platform's own scenario, before a 5% entry fee and 20% carry. The asset: Neuralink — 26 implants, zero revenue, an old chip, and a promised vision product with no human surgery yet. And separately: the deal page says "Opening soon", while the smart contract has been taking money since 22 July.
What it is
The "neura" token on Polygon, issued by Wyoming DAO LLC — the sole investor in a series of the Delaware Binaryx Private Equity Fund Series LLC. After the raise closes, the series is supposed to buy Neuralink shares "through a licensed broker". Neuralink is a private Delaware company at clinical stage with zero revenue. So this is not a share and not even an SPV on a share — it's a token on a stake in a fund that hasn't bought the asset yet.
Four levels of "Neuralink's price" on 3 Sep 2026. Sources are in the text next to the numbers.
1. Money is already being collected while the storefront says "soon"
Deal page on 3 Sep 2026: status "Opening soon", no buy button, a waitlist. The raise's smart contract on Polygon (0xec1D…7827): created 22 Jul 2026, 71 transactions via the "Invest" method, last payment on 1 Sep 2026, a balance of 74,333 USDT. The raise is running privately — via sales managers in messengers — while the public status reads "not yet open". No document says what happens if the allocation isn't filled. Alternative explanations (test transactions, another deal on the same contract) haven't been ruled out.
Sources: app.binaryx.com/en/equity/neuralink and polygonscan.com, 3 Sep 2026.
2. Entry at the top of the range, and the markup eats a third of the upside
The only real round is Series E: $650m at $9bn pre-money / $9.65bn post-money (June 2025); there's been no new primary round and the SEC register is clean. Independent marks: trades at $29–42bn (Caplight via Business Insider, 21 Jul 2026) and $29.8bn / $156 per share (privatemarketview, September 2026). Binaryx: $44bn, and the per-share price differs across the platform's own pages — $245 in the CEO's article versus $257.25 on the deal page.
In the platform's own "$260bn by 2030" scenario, entry at $44bn returns 5.9x, while the same exit from the $29.8bn market mark would return 8.7x: 36% of the upside disappears into the markup before fees (5% entry plus 20% carry).
Sources: TechCrunch 2 Jun 2025 · Business Insider 21 Jul 2026 · privatemarketview 09.2026 · Binaryx pages 13 Jul and 3 Sep 2026.
3. Four layers between the investor and the share
The chain: registered shareholder (a former employee) → an SPV that filed a Form D (the SEC register shows 10 such SPVs on Neuralink since June 2025) → the platform's fund → the token. In documented cases each layer takes 1–2% plus 20% carry and adds about 30 days to payout; in the SpaceX precedent the bottom of the chain waited 8–9 months, and in one reported case the shares had been sold before trading even began. Binaryx names neither the seller of the shares, nor the broker, nor any agent verifying the collateral.
Sources: EDGAR full-text search of Form D filings · TechCrunch 11 Jun 2026 · WSJ via 24/7 Wall St 6 Aug 2026.
4. Who's selling
The operating entity is Wyoming DAO LLC (2022). No licences: "we are not a registered broker-dealer", per the terms of use. The platform's Estonian entity shows as "Deleted" in the Estonian registry (2024). Prior track record — tokenised real estate in Bali: per the platform's own figures, about $8.4m raised across 38 properties, and the company itself acknowledges delays on 5 of 14 projects. Trustpilot rating on 3 Sep 2026: 3.4/5 (the platform's site claims 4.7). Neuralink is the platform's first deal in a new category; Stripe and Revolut are announced on the same template. Neuralink itself is described on the deal page as "not affiliated with and does not endorse Binaryx".
Sources: binaryx.com/terms-of-use · ariregister.rik.ee · Trustpilot 3 Sep 2026.
5. Neuralink itself: linear progress, non-linear promises
Patients with a Neuralink implant. Sources: Reuters via GV Wire 28 Jan 2026 · MobiHealthNews 2 Jul 2026 (26 as of 22 Jun).
Implants: 12 (September 2025) → 21 (January 2026) → 26 (June 2026), all on the old N1 chip (1,024 electrodes); the 3,000-electrode chip promised "this year" isn't in clinical use. Blindsight (vision): no human implants and no registered clinical trial; the timeline slipped from "end of 2026" to "6–12 months" (23 Aug 2026). No revenue. Others are ahead on regulation: China's Neuracle won market approval (13 Mar 2026) and performed its first commercial implant (18 Jul 2026); Paradromics implanted its first patient in June. Historically a 2–5x delay multiplier fits Musk timelines (median 3x across 9 programmes).
For a company with no revenue, "hold for growth" logic doesn't apply at all: what's being sold is a "$130bn by 2028, $260bn by 2030" story, while the asset hasn't yet crossed from clinical trials to real economics.
Sources: Reuters via GV Wire 28 Jan 2026 · MobiHealthNews 2 Jul 2026 · ClinicalTrials.gov 3 Sep 2026 · Gigazine/Xinhua 03.2026.
What tests the view
- 1 Dec 2026 — call: Binaryx will disclose neither the seller of the shares nor an independent attestation for the Neuralink series specifically. If it does, the claim that "unattested collateral carries no information" doesn't hold for new issuers in this class.
- 1 Mar 2027 — call: Blindsight will have no registered clinical trial sponsored by Neuralink. Without delay, registration should have appeared by February 2027; a miss would refute the delay multiplier specifically.
Unknowns
Obtainable: whether the Delaware entities exist in the registry (checkable by hand); the full deal pack (Deal Summary & Terms, subscription agreement) — in the platform's data room after registration; how much has actually been raised — only the contract balance is visible.
Unknowable from outside: Neuralink's stance on SPVs and secondary transfers — no public statements (by contrast, Anthropic declared such transfers void in May 2026, and SpaceX has sent cease-and-desist letters); cap table, share classes, rights of first refusal — undisclosed, so nobody, including the seller, knows whether this chain is enforceable at all; Neuralink's burn and remaining cash — no figure since the June 2025 round.
Who it suits
The real subject of this deal isn't Neuralink but the quality of the intermediary, and that's what fails: an undisclosed seller, no attestation for the series, money collected under a "not yet open" status, and a price 4.6x the round. Even frameworks that allow experimental BCI positions (a common ceiling is a fraction of a percent of a portfolio per name, at valuations up to $10bn) were not written for a $44bn entry. For BCI exposure, cheaper and cleaner routes are waiting for someone in the cohort to list, or looking at public proxies. The minimum bar for any entry into a private company through an intermediary: a named seller of the shares and an attestation for the specific series.
Sources are listed next to each section above.
Research for information only. Not investment advice.